Screening for pancreatic cancer

Advances in Surgery

Volumn 48, Issue 1, 2014, Pages 115-136

  Poruk, Katherine E ^a   Firpo, Matthew A ^b   Mulvihill, Sean J ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Biomarker; Early detection; High risk groups; Pancreatic adenocarcinoma; Prevention; Screening

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; BLOOD; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HUMAN; MASS SCREENING; METHODOLOGY; MORTALITY; PANCREAS TUMOR; PRECANCER; REVIEW; RISK FACTOR; STANDARD; SURVIVAL RATE;

ADENOCARCINOMA; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HUMANS; MASS SCREENING; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906349945     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2014.05.004     Document Type: Review

References (144)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. JAm Coll Surg 1999, 189(1):1-7.
3. Porta M., Fabregat X., Malats N., et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 2005, 7(5):189-197.
4. Poruk K.E., Firpo M.A., Adler D.G., et al. Screening for pancreatic cancer: why, how, and who?. Ann Surg 2013, 257(1):17-26.
5. Key C. Cancer of the pancreas. In: Ries LA, Young JL, Keel GE, etal, editors. Cancer survival among adults: US SEER Program, 1988-2001: patient and tumor characteristics. 2007.
6. SEER cancer statistics review, 1975-2010 2013, National Cancer Institute, Bethesda (MD). N. Howlader, A.M. Noone, M. Krapcho (Eds.).
7. Crile G. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 1970, 130(6):1049-1053.
8. Crist D.W., Sitzmann J.V., Cameron J.L. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987, 206(3):358-365.
9. Birkmeyer J.D., Siewers A.E., Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. NEngl J Med 2002, 346(15):1128-1137.
10. Glasgow R.E., Jackson H.H., Neumayer L., et al. Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. JAm Coll Surg 2007, 204(6):1252-1260.
11. Birkmeyer J.D., Warshaw A.L., Finlayson S.R., et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999, 126(2):178-183.
12. Parikh P., Shiloach M., Cohen M.E., et al. Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB (Oxford) 2010, 12(7):488-497.
13. Bruzoni M., Johnston E., Sasson A.R. Pancreatic incidentalomas: clinical and pathologic spectrum. Am J Surg 2008, 195(3):329-332. [discussion: 32].
14. Karatzas T., Dimitroulis D., Charalampoudis P., et al. Management of cystic and solid pancreatic incidentalomas: a review analysis. JBUON 2013, 18(1):17-24.
15. Lahat G., Ben Haim M., Nachmany I., et al. Pancreatic incidentalomas: high rate of potentially malignant tumors. JAm Coll Surg 2009, 209(3):313-319.
16. Winter J.M., Cameron J.L., Lillemoe K.D., et al. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg 2006, 243(5):673-680. [discussion: 80-3].
17. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. JClin Oncol 2007, 25(16):2212-2217.
18. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. JClin Oncol 2006, 24(24):3946-3952.
19. Abou-Alfa G.K., Letourneau R., Harker G., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. JClin Oncol 2006, 24(27):4441-4447.
20. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. JClin Oncol 1997, 15(6):2403-2413.
21. Colucci G., Labianca R., Di Costanzo F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. JClin Oncol 2010, 28(10):1645-1651.
22. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. NEngl J Med 2011, 364(19):1817-1825.
23. Cunningham D., Chau I., Stocken D.D., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. JClin Oncol 2009, 27(33):5513-5518.
24. Kindler H.L., Niedzwiecki D., Hollis D., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). JClin Oncol 2010, 28(22):3617-3622.
25. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. JClin Oncol 2005, 23(15):3509-3516.
26. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol 2007, 25(15):1960-1966.
27. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. JClin Oncol 2010, 28(22):3605-3610.
28. Poplin E., Feng Y., Berlin J., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. JClin Oncol 2009, 27(23):3778-3785.
29. Riess H., Helm A., Niedergethmann I. Arandomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine alone in patients with advanced pancreatic cancer. JClin Oncol 2005, 23(Suppl 16):1092. [abstract: 4009].
30. Spano J.P., Chodkiewicz C., Maurel J., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371(9630):2101-2108.
31. Stathopoulos G.P., Syrigos K., Aravantinos G., et al. Amulticenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006, 95(5):587-592.
32. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. JClin Oncol 2009, 27(13):2231-2237.
33. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. NEngl J Med 2013, 369(18):1691-1703.
34. O'Shaughnessy M., Konety B., Warlick C. Prostate cancer screening: issues and controversies. Minn Med 2010, 93(8):39-44.
35. Esserman L., Shieh Y., Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302(15):1685-1692.
36. Walsh J.M., Terdiman J.P. Colorectal cancer screening: scientific review. JAMA 2003, 289(10):1288-1296.
37. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. NEngl J Med 1993, 328(19):1365-1371.
38. Warren J.B., Gullett H., King V.J. Cervical cancer screening and updated Pap guidelines. Prim Care 2009, 36(1):131-149. ix.
39. Vesco K.K., Whitlock E.P., Eder M., et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155(10):698-705. W216.
40. Shen Y., Yang Y., Inoue L.Y., et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. JNatl Cancer Inst 2005, 97(16):1195-1203.
41. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. NEngl J Med 2005, 353(17):1784-1792.
42. Gotzsche P.C., Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009, (4). CD001877.
43. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. JNatl Cancer Inst 1999, 91(12):1017-1024.
44. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. NEngl J Med 2009, 360(13):1320-1328.
45. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. NEngl J Med 2009, 360(13):1310-1319.
46. Carroll P.R., Whitson J.M., Cooperberg M.R. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?. JClin Oncol 2011, 29(4):345-347.
47. Loeb S., Vonesh E.F., Metter E.J., et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?. JClin Oncol 2011, 29(4):464-467.
48. The National Lung Screening Trial, Aberle D.R., Berg C.D., et al. Overview and study design. Radiology 2011, 258(1):243-253.
49. Menon U., Gentry-Maharaj A., Hallett R., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10(4):327-340.
50. Buys S.S., Partridge E., Black A., et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305(22):2295-2303.
51. Croswell J.M., Ransohoff D.F., Kramer B.S. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010, 37(3):202-215.
52. Yachida S., Jones S., Bozic I., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467(7319):1114-1117.
53. Hassan M.M., Bondy M.L., Wolff R.A., et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007, 102(12):2696-2707.
54. Lynch S.M., Vrieling A., Lubin J.H., et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009, 170(4):403-413.
55. Lowenfels A.B., Maisonneuve P. Risk factors for pancreatic cancer. JCell Biochem 2005, 95(4):649-656.
56. Silverman D.T., Schiffman M., Everhart J., et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999, 80(11):1830-1837.
57. Ansary-Moghaddam A., Huxley R., Barzi F., et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev 2006, 15(12):2435-2440.
58. Chari S.T., Leibson C.L., Rabe K.G., et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005, 129(2):504-511.
59. Pannala R., Leibson C.L., Rabe K.G., et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009, 104(9):2318-2325.
60. Vrieling A., Bueno-de-Mesquita H.B., Boshuizen H.C., et al. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010, 126(10):2394-2403.
61. Zheng W., McLaughlin J.K., Gridley G., et al. Acohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 1993, 4(5):477-482.
62. Li D., Morris J.S., Liu J., et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009, 301(24):2553-2562.
63. Lowenfels A.B., Maisonneuve P., Cavallini G., et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. NEngl J Med 1993, 328(20):1433-1437.
64. Bansal P., Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995, 109(1):247-251.
65. Malka D., Hammel P., Maire F., et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51(6):849-852.
66. Chow W.H., Johansen C., Gridley G., et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999, 79(3-4):640-644.
67. Jacobs E.J., Chanock S.J., Fuchs C.S., et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010, 127(6):1421-1428.
68. Permuth-Wey J., Egan K.M. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 2009, 8(2):109-117.
69. Thompson D., Easton D.F. Cancer Incidence in BRCA1 mutation carriers. JNatl Cancer Inst 2002, 94(18):1358-1365.
70. Lynch H.T., Deters C.A., Snyder C.L., et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005, 158(2):119-125.
71. Al-Sukhni W., Rothenmund H., Borgida A.E., et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet 2008, 124(3):271-278.
72. Shi C., Hruban R.H., Klein A.P. Familial pancreatic cancer. Arch Pathol Lab Med 2009, 133(3):365-374.
73. Korsse S.E., Harinck F., van Lier M.G., et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. JMed Genet 2013, 50(1):59-64.
74. Hearle N., Schumacher V., Menko F.H., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006, 12(10):3209-3215.
75. Giardiello F.M., Offerhaus G.J., Lee D.H., et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993, 34(10):1394-1396.
76. Kastrinos F., Mukherjee B., Tayob N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302(16):1790-1795.
77. McBride K.A., Ballinger M.L., Killick E., et al. Li-Fraumeni syndrome; cancer risk assessment and clinical management. Nature Reviews Clinical Oncology 2014, 11:260-271.
78. Brentnall T.A., Bronner M.P., Byrd D.R., et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999, 131(4):247-255.
79. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2(7):606-621.
80. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4(6):766-781. [quiz: 665].
81. Chu D., Kohlmann W., Adler D.G. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP 2010, 11(3):203-212.
82. Klapman J., Malafa M.P. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 2008, 15(4):280-287.
83. Langer P., Kann P.H., Fendrich V., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58(10):1410-1418.
84. Ludwig E., Olson S.H., Bayuga S., et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011, 106(5):946-954.
85. Poley J.W., Kluijt I., Gouma D.J., et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009, 104(9):2175-2181.
86. Verna E.C., Hwang C., Stevens P.D., et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010, 16(20):5028-5037.
87. Hruban R.H., Goggins M., Parsons J., et al. Progression model for pancreatic cancer. Clin Cancer Res 2000, 6(8):2969-2972.
88. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001, 25(5):579-586.
89. Kozuka S., Sassa R., Taki T., et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979, 43(4):1418-1428.
90. Andea A., Sarkar F., Adsay V.N. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003, 16(10):996-1006.
91. Cubilla A.L., Fitzgerald P.J. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976, 36(7 PT 2):2690-2698.
92. Shi C., Klein A.P., Goggins M., et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009, 15(24):7737-7743.
93. Hruban R.H., Maitra A., Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008, 1(4):306-316.
94. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
95. Lohr M., Kloppel G., Maisonneuve P., et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005, 7(1):17-23.
96. Brockie E., Anand A., Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann Diagn Pathol 1998, 2(5):286-292.
97. Brat D.J., Lillemoe K.D., Yeo C.J., et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998, 22(2):163-169.
98. Sohn T.A., Yeo C.J., Cameron J.L., et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004, 239(6):788-797. [discussion: 97-9].
99. Tanaka M., Chari S., Adsay V., et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006, 6(1-2):17-32.
100. Wada K., Kozarek R.A., Traverso L.W. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg 2005, 189(5):632-636. [discussion: 7].
101. Brune K., Hong S.M., Li A., et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3536-3542.
102. Blackford A., Serrano O.K., Wolfgang C.L., et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009, 15(14):4674-4679.
103. Kim J., Reber H.A., Dry S.M., et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 2006, 55(11):1598-1605.
104. Poruk K.E., Gay D.Z., Brown K., et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 2013, 13(3):340-351.
105. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. JClin Oncol 2006, 24(33):5313-5327.
106. Tempero M.A., Uchida E., Takasaki H., et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987, 47(20):5501-5503.
107. Barton J.G., Bois J.P., Sarr M.G., et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. JGastrointest Surg 2009, 13(11):2050-2058.
108. Reni M., Cereda S., Balzano G., et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009, 115(12):2630-2639.
109. Berger A.C., Garcia M., Hoffman J.P., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. JClin Oncol 2008, 26(36):5918-5922.
110. Harsha H.C., Kandasamy K., Ranganathan P., et al. Acompendium of potential biomarkers of pancreatic cancer. PLoS Med 2009, 6(4):e1000046.
111. Cui Y., Andersen D.K. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012, 19(5):F9-F26.
112. Gold D.V., Modrak D.E., Ying Z., et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. JClin Oncol 2006, 24(2):252-258.
113. Grote T., Logsdon C.D. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 2007, 23(5):508-514.
114. Ibis M., Koklu S., Yilmaz F.M., et al. Serum adenosine deaminase levels in pancreatic diseases. Pancreatology 2007, 7(5-6):526-530.
115. Koopmann J., Fedarko N.S., Jain A., et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004, 13(3):487-491.
116. Koopmann J., Rosenzweig C.N., Zhang Z., et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006, 12(2):442-446.
117. Kuhlmann K.F., van Till J.W., Boermeester M.A., et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(5):886-891.
118. Melle C., Ernst G., Escher N., et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem 2007, 53(4):629-635.
119. Rosty C., Christa L., Kuzdzal S., et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002, 62(6):1868-1875.
120. Simeone D.M., Ji B., Banerjee M., et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007, 34(4):436-443.
121. Brand R.E., Nolen B.M., Zeh H.J., et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011, 17(4):805-816.
122. Firpo M.A., Gay D.Z., Granger S.R., et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 2009, 33(4):716-722.
123. Zhou W., Sokoll L.J., Bruzek D.J., et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998, 7(2):109-112.
124. Zhang L., Farrell J.J., Zhou H., et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010, 138(3):949-957.e1-7.
125. Friel A.M., Corcoran C., Crown J., et al. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res Treat 2010, 123(3):613-625.
126. Rabinowits G., Gercel-Taylor C., Day J.M., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009, 10(1):42-46.
127. Skog J., Wurdinger T., van Rijn S., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10(12):1470-1476.
128. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110(1):13-21.
129. Bryzgunova O.E., Morozkin E.S., Yarmoschuk S.V., et al. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci 2008, 1137:222-225.
130. Chan K.C., Lai P.B., Mok T.S., et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008, 54(9):1528-1536.
131. Ellinger J., Albers P., Perabo F.G., et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. JUrol 2009, 182(1):324-329.
132. Radpour R., Barekati Z., Kohler C., et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 2011, 6(1):e16080.
133. Kurihara T., Itoi T., Sofuni A., et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. JHepatobiliary Pancreat Surg 2008, 15(2):189-195.
134. Stott S.L., Hsu C.H., Tsukrov D.I., et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010, 107(43):18392-18397.
135. Shi C., Fukushima N., Abe T., et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008, 7(3):353-360.
136. Suehara N., Mizumoto K., Tanaka M., et al. Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis. Clin Cancer Res 1997, 3(12 Pt 1):2479-2483.
137. Uehara H., Nakaizumi A., Tatsuta M., et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol 1999, 94(9):2513-2518.
138. Volmar K.E., Vollmer R.T., Routbort M.J., et al. Pancreatic and bile duct brushing cytology in 1000 cases: review of findings and comparison of preparation methods. Cancer 2006, 108(4):231-238.
139. Long E.E., Van Dam J., Weinstein S., et al. Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surg Oncol 2005, 14(2):105-113.
140. DeWitt J., Devereaux B., Chriswell M., et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004, 141(10):753-763.
141. Sahani D.V., Shah Z.K., Catalano O.A., et al. Radiology of pancreatic adenocarcinoma: current status of imaging. JGastroenterol Hepatol 2008, 23(1):23-33.
142. Bluemke D.A., Fishman E.K. CT and MR evaluation of pancreatic cancer. Surg Oncol Clin N Am 1998, 7(1):103-124.
143. Beinfeld M.T., Wittenberg E., Gazelle G.S. Cost-effectiveness of whole-body CT screening. Radiology 2005, 234(2):415-422.
144. Poruk K.E., Firpo M.A., Huerter L.M., et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19(10):2605-2610.